Photo of Lisa A. Adelson

Lisa A. Adelson

Subscribe to Lisa A. Adelson's Posts

Lisa Adelson is a counsel with the Intellectual Property Group in Crowell & Moring LLP's Washington, D.C. office. Lisa is a seasoned patent practitioner with numerous years of experience representing biotechnology, pharmaceutical, and design clients in all aspects of patent prosecution and counseling.

Lisa has extensive experience managing patent portfolios and conducting analyses related to major due diligence and patent litigation matters. Lisa has represented clients before the U.S. Patent and Trademark Office, the Patent Trial and Appeal Board (formerly the Board of Patent Appeals and Interferences), and the U.S. Court of Appeals for the Federal Circuit.

Before joining Crowell & Moring, Lisa spent many years as a patent attorney at a leading AmLaw 100 firm in Washington, D.C. In that role, Lisa assisted in a wide array of biotechnology and pharmaceutical clients with their patent-related needs, including preparation, prosecution, counseling, litigation, due diligence, and related regulatory work. Lisa also has significant experience in the field of design patent law, having practiced alongside one of the pioneers in this field at a Washington-area boutique.

Lisa earned her J.D. from Georgetown University Law School and her B.A., magna cum laude, from Colgate University, where she was a Colgate University Alumni Memorial Scholar, a Dana Scholar, and a lifetime member and president of Phi Eta Sigma Honor Society. She also received the Dean's Award for Academic Excellence. Additionally, Lisa has received the Bausch and Lomb Science Prize, American Chemical Society Award, and Harvard Book Award.

Lisa is a strategic thinker who has represented individual and multinational clients at all phases of development. She is a frequent lecturer on current topics in intellectual property law and has published various articles in the field of patent law.

Contact:Read more about Lisa A. Adelson

On October 28, 2015, the U.S. Copyright Office of the Library of Congress (the “Office”) issued a Final Rule containing several exemptions to the Digital Millennium Copyright Act that expanded access to medical device computer programs and the patient data they generate.  The Digital Millennium Copyright Act allows intellectual property holders to install “technological protection measures” (TPMs) in their software which blocks unauthorized inspection of data to protect copyright.  Under the Act, the Library of Congress grants exemptions to TPMs every three years.

In the Final Rule, the Office included an exemption for researchers investigating computer programs on devices and machines for good faith security research. The Office found that legitimate security research has been hindered by TPMs that limit access.  Covered devices include medical devices used for patient implantation or corresponding personal monitoring systems, as long as they are not used by patients or for patient care.  The research exemption begins 12 months after the regulation’s effective date, meaning it starts on October 28, 2016.  Additionally, the Office created an exemption for patients who seek to passively access information that is already being generated by their own medical devices or personal monitoring systems.  Unlike the research exemption, the patient monitoring exemption takes effect immediately, and it is limited to patients themselves, as opposed to researchers or other parties.Continue Reading U.S. Copyright Office Authorizes New Access to Medical Device Programs and Data under Digital Millennium Copyright Act